Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial
June 17, 2022 | Aditya Bardia, MD, MPHVideo Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current Time 0:00Duration 0:00Remaining Time 0:00Video Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current Time 0:00Duration 0:00Remaining Time 0:00Dr Aditya Bardia reviews recently published data from the EMERALD trial on elacestrant versus endocrine therapy in…
